Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1994-05-17
1996-10-15
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514170, 514177, 514178, 514179, 514182, 424422, 424423, 424424, 424425, 424426, 424484, 424485, 424486, 424487, 424488, A61K 3156
Patent
active
055654436
DESCRIPTION:
BRIEF SUMMARY
This invention relates to novel compositions endowed with progestative action and the processes for their production.
It has more particularly as a subject matter novel compositions intended to insure protracted contraception.
Specifically it has as a subject matter, a preparation in the form of a subcutaneous implant containing an effective amount of a derivative of 3-substituted 6-methyl 17.alpha.-OR.sub.1 20-oxo 19-nor pregna 4,6-dien selected from the group consisting of general formula I ##STR1## wherein R.sub.1 is a hydrogen, or the acyl moiety of an organic aliphatic, aromatic or cyclanic carboxylic acid having from 2 to 16 carbon atoms pregna 4,6-diens of general formula II ##STR2## wherein R.sub.1 has the above-given definitions and R.sub.2 is a hydrogen., the acyl moiety of carboxylic acid, or an alkyl radical having from 1 to 8 carbon atoms and formula III ##STR3## wherein R.sub.1 is defined as above R.sub.3 and R.sub.4 together form either an oximido grouping of formula .dbd.N--O--R.sub.5 wherein R.sub.5 is a hydrogen, a lower alkyl or a carboxyalkyl group or an alkylenedioxy grouping which may be substituted or each are a lower alkoxy radical in admixture or conjunction with a carrier and with a biologically acceptable diluent.
The implants according to this inventions are made of polymeric materials (hydrophobic, hydrophilic or biodegradable) used as vectors of pharmacologically-active compounds previously included in the formulae I, II or III.
The implants namely are of the container type or of the matrix type.
Among the implants which utilize hydrophobic materials it may be cited: for example SILASTIC.RTM. (medical grade of dimethylpolysiloxane made by Dow Corning) produced by the company Dow Corning. This kind of implant is shown in the form of a tube having an external diameter comprised between 2 and 4 mm and having a thickness of about 0.4 mm. The portions of tubing are cut at the selected lengths as a function of the amount of nor pregnadienic compound which is desirably incorporated. The ends of these portions of tube are closed using a glue of medical quality also sold by the company Dow Corning and which belongs to the group of silicones RTV (Room Temperature Vulcanizing).
The amount of nor pregnadienic compound of formulae I, II or III incorporated in the portion of the tube, ranges from 30 to 80 mg and preferably from 45 to 65 mg. This content of active ingredient is namely determined by the granulometric properties of the active ingredient which may be micronized or microcristallized and by its physico-chemical characteristics (molecular weight, solubility, diffusibility, partition index). The way of incorporation of the active ingredient may be done either in the solid state or dispersed in a biologically acceptable and inert carrier.
The manner of preparation and isolation of the microcrystallized forms of the compounds of this invention have already been described in the french patent application 2.668.945 in the name of the applicant. copolymers such as for example the material sold under the Trade Name ELVAX.RTM. MD 40 (ethylene-vinyl acetate copolymer) by the company DUPONT de NEMOURS. This kind of implant has already been utilized for the intra uterine device Progestasert.RTM. containing an hormonal preparation made by Alza, but contrarily to Progestasert in the case of the implants of this invention, the active ingredient is introduced in a solid form. kind of implant has already been used in man (Nash, Robertson and cowork--Contraception 18 (1978) p.367). This implant of the matrix type namely presents the inconvenient of a high rate of release of the active ingredient. In order to compensate this disadvantage, the implants according to this invention have to be produced in introducing one of the derivatives according to the formulae I, II or III suspended in a hydrophilic liquid in which the active ingredient is insoluble. This suspension is admixed to the poly dimethyl siloxanes then the whole mass is cross-linked before to proceed to the extrusion of the elastomer in
REFERENCES:
patent: 4147783 (1979-04-01), van der Vies
patent: 4172132 (1979-10-01), Draper et al.
patent: 4456601 (1984-06-01), Toth et al.
patent: 4544555 (1985-10-01), Gastaud
patent: 5223492 (1993-06-01), Nasraoui et al.
Nash et al "Steroid Release From Silastic Capsules and Rods" Contraception Oct. 1978, vol. 18, No. 4, pp. 367-394.
Metzker "One Year Contraception with a Single Subdermal Implant Containing Nomegestrol Acetate" Contraception vol. 47, pp. 97-105.
Coutinho Elsimar
Lanquetin Michel
Paris Jacques
Thomas Jean-Louis
Laboratoire Theramex S.A.
Nutter Nathan M.
LandOfFree
Subcutaneous implants based on normegestrol derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Subcutaneous implants based on normegestrol derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Subcutaneous implants based on normegestrol derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1246205